Anaptysbio (ANAB) Common Equity (2016 - 2026)
Anaptysbio (ANAB) recorded Common Equity of $12.75 million in Q1 2026, down 62.5% from $34.02 million a year earlier and down 65.7% from the prior quarter.
Powered by 
Analysis
Anaptysbio (ANAB) Common Equity (2016 - 2026) Analysis & Trends
At the end of FY2025, Anaptysbio reported Common Equity of $37.21 million, down 47.5% from FY2024.
- Annual Common Equity has declined for seven straight years, with a five-year compound annual growth rate of -37.7% (FY2020 to FY2025).
- Across earlier years, Common Equity came in at $70.87 million in FY2024 (-19.6%), $88.1 million in FY2023 (-66.4%), $262.1 million in FY2022 (-26.5%) and $356.43 million in FY2021 (-10.2%).
- Quarterly Common Equity has ranged from -$44.73 million in Q2 2025 to $385.73 million in Q2 2021 over the past five years.
- Peak year-over-year performance for Common Equity in the last five years was growth of 6.5% in Q3 2021, against a decline of 93.3% in Q2 2024 at the low end.
- Per Business Quant, the preceding three quarters came in at $37.21 million (Q4 2025), -$29.42 million (Q3 2025) and -$44.73 million (Q2 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 33.88 Bn |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 84.97 Bn |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | -5.94 Bn |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | 41.98 Bn |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | 41.95 Bn |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 50.37 Bn |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 11.69 Bn |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | 11.83 Bn |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 85.49 Bn |
| 10 | Anaptysbio | 1.37 Bn | 260.54 Mn | - | 12.75 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 12.75 Mn |
| Dec 31, 2025 | 37.21 Mn |
| Sep 30, 2025 | -29.42 Mn |
| Jun 30, 2025 | -44.73 Mn |
| Mar 31, 2025 | 34.02 Mn |
| Dec 31, 2024 | 70.87 Mn |
| Sep 30, 2024 | 84.37 Mn |
| Jun 30, 2024 | 9.88 Mn |
| Mar 31, 2024 | 47.78 Mn |
| Dec 31, 2023 | 88.10 Mn |
| Sep 30, 2023 | 120.38 Mn |
| Jun 30, 2023 | 148.45 Mn |
| Mar 31, 2023 | 191.09 Mn |
| Dec 31, 2022 | 262.10 Mn |
| Sep 30, 2022 | 277.62 Mn |
| Jun 30, 2022 | 304.31 Mn |
| Mar 31, 2022 | 330.75 Mn |
| Dec 31, 2021 | 356.43 Mn |
| Sep 30, 2021 | 383.61 Mn |
| Jun 30, 2021 | 385.73 Mn |
API Access
Anaptysbio Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=ANAB&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "ANAB", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=ANAB&period=max&api_key=YOUR_API_KEY");
const data = await res.json();